Upregulation of the ERG11 gene in candida krusei by azoles

DARU, Journal of Pharmaceutical Sciences

Volumn 18, Issue 4, 2010, Pages 276-280

  Tavakoli, M ^a   Zaini, F ^a   Kordbacheh, M ^a   Safara, M ^a   Raoofian, R ^b   Heidari, M ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug resistance; Gene expression; Polymorphism; RT PCR

Indexed keywords

FLUCONAZOLE; FUNGAL PROTEIN; ITRACONAZOLE; MESSENGER RNA; PROTEIN ERG11; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA KRUSEI; CODON; CONTROLLED STUDY; DNA SEQUENCE; FUNGUS ISOLATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HETEROZYGOSITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 79251469064     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the scope program. Diagnostic microbiology and infectious disease, 1998; 30: 121-129.
2. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. Journal of clinical microbiology, 2004; 42: 1519-1527.
3. Ostrosky-Zeichner L, Rex JH, Pappas P.G, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the united states. Antimicrobial agents and chemotherapy, 2003; 47: 3149-3154.
4. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clinical Microbiology & Infection, 2004; 10: 11-23.
5. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro susceptibilities of rare Candida bloodstream isolavtes to ravuconazole and three comparative antifungal agents. Diagnostic Microbiology & Infectious Disease, 2004; 48: 101-105.
6. Hsueh PR, Teng LJ, Ho SW, Luh K.T. Catheter-related sepsis due to Rhodotorula glutinis. Journal of Clinical Microbiology, 2003; 41: 857-859.
7. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clinical infectious diseases, 1995: 115-125.
8. Pappas PG, Rex J.H, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Guidelines for treatment of candidiasis. Clinical Infectious Diseases, 2003; 38: 161-189.
9. Kennedy MA, Barbuch R, Bard M. Transcriptional regulation of the squalene synthase gene (erg9) in the yeast Saccharomyces cerevisiae. Biochim Biophys Acta, 1999; 1445: 110-122.
10. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother, 1998; 42: 3065-3072.
11. Venkateswarlu K, Denning DW, Kelly SL. Inhibition and interaction of cytochrome p450 of Candida krusei with azole antifungal drugs. J Med Vet Mycol, 1997; 35: 19-25.
12. Fukuoka T, Johnston DA, Winslow CA, de Groot MJ, Burt C, Hitchcock CA, Filler SG. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother, 2003; 47: 1213-1219.
13. Orozco AS, Higginbotham L.M, Hitchcock CA, Parkinson T, Falconer D, Ibrahim AS, Ghannoum MA Filler S G. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother, 1998; 42: 2645-2649.
14. Guinea J, Sanchez-Somolinos M, Cuevas O, Pelaez T, Bouza E. Fluconazole resistance mechanisms in Candida krusei: The contribution of efflux-pumps. Med Mycol, 2006; 44: 575-578.
15. Zaini F, Kordbacheh P, Khedmati E, Safara M, Gharaeian N. Performance of five phenotypical methods for identification of Candida isolates from clinical materials Iranian J Pub Health, 2006; 35: 25-32.
16. Najafzadeh MJ, Falahati M, Pooshanga Bagheri K, Fata A, Fateh R, Fateh R. Flow cytometry susceptibility testing for conventional antifungal drugs and Comparison with the NCCLS Broth Macrodilution Test, DARU, 2009; 17: 94-98.
17. Saffari M, Dinehkabodi OS, Ghaffari SH, Modarressi MH, Mansouri F, Heidari M. Identification of novel p53 target genes by cDNA AFLP in glioblastoma cells. Cancer Lett, 2009; 273: 316-22
18. Ousati Ashtiani Z, Ayati M, Modarresi MH, Raoofian R, Sabah Goulian B, Greene WK, Heidari M. Association of TGIFLX/Y mRNA expression with prostate cancer. Med Oncol, 2009; 26: 73-7
19. Aarabi M, Ousati-Ashtiani Z, Nazarian A, Modarressi MH, Heidari M. Association of TGIFLX/Y mRNA expression with azoospermia in infertile men. Mol Reprod Dev, 2008; 75: 1761-6
20. Henry KW, Nickels J.T, Edlind T.D. Upregulation of erg genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrobial agents and chemotherapy, 2000; 44: 2693-2700.
21. Kakeya H, Miyazaki T, Miyazaki Y, Kono S. Azole resistance in Candida spp. Japanese Journal of Medical Mycology, 2003; 44: 87-92.
22. Pinjon E, Moran GP, Jackson CJ, Kelly SL, Sanglard D, Coleman D.C, Sullivan DJ. Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrobial agents and chemotherapy, 2003; 47: 2424-2437.
23. Chau AS, Gurnani M, Hawkinson R, Laverdiere M, Cacciapuoti A, McNicholas PM. Inactivation of sterol 5, 6-desaturase attenuates virulence in Candida abicans. Antimicrobial agents and chemotherapy, 2005; 49: 3646-3651.
24. Yan L, Zhang J, Li M, Cao Y, Xu Z, Cao Y, Gao P, Wang Y, Jiang Y. DNA microarray analysis of fluconazole resistance in a laboratory Candida albicans strain. Acta Biochim Biophys Sin, 2008; 40: 1048-1060.
25. Venkateswarlu K, Denning D.W, Manning NJ, Kelly S.L. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother, 1996; 40: 2443-2446.
26. Katiyar SK, Edlind TD. Identification and expression of multidrug resistance related abc transporter genes in Candida krusei. Medical Mycology, 2001; 39: 109-116.
27. Lamping E, Ranchod A, Nakamura K, Tyndall JDA, Niimi K, Holmes AR, Niimi M, Cannon RD. Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrobial Agents and Chemotherapy, 2009; 53: 354-369.
28. Clark FS, Parkinson T, Hitchcock CA, Gow NA. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: Possible role for drug efflux in drug resistance. Antimicrobial Agents and Chemotherapy, 1996; 40: 419-425.
29. Marichal P, Gorrens J, Coene MC, Le Jeune L, Bossche HV. Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses, 1995; 38: 111-117.
30. Dimster-Denk D, Rine J. Transcriptional regulation of a sterol-biosynthetic enzyme by sterol levels in Saccharomyces cerevisiae. Molecular and Cellular Biology, 1996; 16: 3981-3989.
31. Asai K, Tsuchimori N, Okonogi K, Perfect JR, Gotoh O, Yoshida Y. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase p450. Antimicrobial agents and chemotherapy, 1999; 43: 1163-1169.
32. Beyer A, Hollunder J, Nasheuer HP, Wilhelm T. Post-transcriptional expression regulation in the yeast Saccharomyces cerevisiae on a genomic scale. Molecular & Cellular Proteomics, 2004; 3: 1083-1092.